Topics

Glioblastoma | Diagnosis | Methylation

Home > Publications > Topics > Glioblastoma > Diagnosis > Methylation

Sanada T, Kinoshita M, Sasaki T, Yamamoto S, Fujikawa S, Fukuyama S, Hayashi N, Fukai J, Okita Y, Nonaka M, Uda T, Arita H, Mori K, Ishibashi K, Takano K, Nishida N, Shofuda T, Yoshioka E, Kanematsu D, Tanino M, Kodama Y, Mano M, Kanemura Y.
Prediction of MGMT promotor methylation status in glioblastoma by contrast-enhanced T1-weighted intensity image.
Neurooncol Adv. 2024 Feb 1;6(1):vdae016. doi: 10.1093/noajnl/vdae016. PMID: 38410136. Observational study. ˍ

Liu X, Han T, Wang Y, Liu H, Zhou J.
Prediction of O(6)-methylguanine-DNA methyltransferase promoter methylation status in IDH-wildtype glioblastoma using MRI histogram analysis.
Neurosurg Rev. 2024 Jun 22;47(1):285. doi: 10.1007/s10143-024-02522-w. PMID: 38907038. Observational study˰ ˍ

*Huseyinoglu Z, Uysal E, Inan MA, Demirci T, Gokay G, Aras FK, Erdamar S, Ozduman K, Pamir MN, Danyeli AE.
Optimal qMSP cutoff value for MGMT promoter methylation in glioblastoma and its validation for clinical significance.
BMC Cancer. 2025 Nov 28;25(1):1833. doi: 10.1186/s12885-025-15225-2. PMID: 41316075. Observational study. ˍ

Lehmann U.
Clinical diagnostic utility of MGMT promoter methylation.
Epigenomics. 2026 Jun 17:1-12. doi: 10.1080/17501911.2026.2688974. PMID: 42307140˰ ˍ